Company Dossier · Health Care
Natera
- Russell 1000
What Natera is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $2.71 billion, up 38% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.08 billion, down 20% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.14 billion, up 75% from a year earlier.SEC EDGAR filings (XBRL)
- Long-term debt issued in the fiscal year to December 31, 2017: $0.08 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 6, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 3 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 27, 2026): 2 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $89.6 million on the open market.SEC Form 4
- 847 institutional managers reported a position at June 30, 2026 (+81 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 35 (36 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for Natera yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Natera: earnings call confidence
Palanor Discourse score per call, 0 to 1
Hiring and ownership
In the news
Headlines that name Natera, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralNatera Inc (NTRA) Shares Surge 3.7% -- What GF Score of 71 Tells Investors
gurufocus.com · via Marketaux · Oct 5, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)third_quarter 2026
- Oct 19, 2026LobbyingLobbying report (ERVIN GRAVES STRATEGY GROUP, LLC)third_quarter 2026 · $0.1 million
- Oct 19, 2026LobbyingLobbying report (LMH STRATEGIC SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 16, 2026LobbyingLobbying report (NATERA INC)third_quarter 2026 · $0.2 million
- Oct 6, 2026Patent
- Sep 29, 2026Patent
- Sep 22, 2026Patent
- Sep 15, 2026Patent
- Sep 15, 2026Patent
- Jul 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)second_quarter 2026
- Jul 19, 2026LobbyingLobbying report (ERVIN GRAVES STRATEGY GROUP, LLC)second_quarter 2026 · $0.1 million
- Jul 10, 2026LobbyingLobbying report (NATERA INC)second_quarter 2026 · $0.1 million
- Jul 6, 20268-KDirector or officer changeItem 5.02
- Jul 5, 2026LobbyingLobbying report (LMH STRATEGIC SOLUTIONS)second_quarter 2026 · $0.0 million
- Jun 16, 20268-KDirector or officer changeItem 5.02
- Jun 16, 20268-KDirector or officer changeItem 5.02
- Jun 16, 20268-KShareholder vote resultsItem 5.07
- Jun 5, 20268-KDirector or officer changeItem 5.02
- Apr 1, 20268-KDirector or officer changeItem 5.02
- Feb 27, 202610-KAnnual report (10-K)2 risk factors added, 0 removed
- Dec 10, 2025S-1
- Jun 18, 20258-KDirector or officer changeItem 5.02
- Jun 18, 20258-KShareholder vote resultsItem 5.07
- Mar 12, 20258-KDirector or officer changeItem 5.02
- Feb 28, 202510-KAnnual report (10-K)0 risk factors added, 6 removed
- Dec 6, 20248-KDirector or officer changeItem 5.02
- Feb 29, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Medpace MEDP | $2.8B | $0.7B | Jun 30, 2026 |
| Chemed Corporation CHE | $2.6B | $0.3B | Jun 30, 2026 |
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| Hims & Hers Health HIMS | $2.6B | $0.1B | Jun 30, 2026 |
| Envista NVST | $2.9B | $0.3B | Jul 3, 2026 |
| Royalty Pharma RPRX | $2.5B | — | Jun 30, 2026 |
| Revvity RVTY | $2.9B | $0.6B | Jul 5, 2026 |
| Exelixis EXEL | $2.4B | $1.2B | Jul 3, 2026 |